Skip to main content
SpringerLink
Log in

The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project

  • T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of lymphoid malignancies that portend a poor prognosis and have an undefined optimal therapeutic strategy. Data on best practices stem from prior studies that have generally included B cell lymphomas. However, the enhanced ability to diagnose PTCLs, the development of newer agents specific for PTCLs, and its increased incidence have called the scientific community to develop better strategies to combat these neoplasms. To that end, T cell lymphoma registries were developed in an attempt to answer relevant questions on the prognosis and management of PTCLs. The largest registries currently enrolling patients are the Comprehesive Oncology Measures for PeripheraL T-cEll Lymphoma TrEatment (COMPLETE) and the T-Cell Project. Despite the inherent limitations of these studies, valuable information are being collected to refine our management approaches and to aid in designing future clinical trials. This review illustrates the value of these registries and describes the critical questions that need to be answered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17(12):3835–49.

    CAS  PubMed  Google Scholar 

  2. Jaffe ES, Harris NLJWV. Tumours of haematopoietic and lymphoid tissues—pathology and genetics, World Health Organization of Tumours. Lyon: IARC Press; 2001.

    Google Scholar 

  3. Picker LJ, Weiss LM, Medeiros LJ, Wood GS, Warnke RA. Immunophenotypic criteria for the diagnosis of non-Hodgkin’s lymphoma. Am J Pathol. 1987;128(1):181–201.

    PubMed Central  CAS  PubMed  Google Scholar 

  4. Cooke CB, Krenacs L, Stetler-Stevenson M, et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood. 1996;88(11):4265–74.

    CAS  PubMed  Google Scholar 

  5. Delves PJ, Roitt IM. The immune system. first of two parts. N Engl J Med. 2000;343(1):37–49.

    Article  CAS  PubMed  Google Scholar 

  6. Delves P, Roitt I. Advances in immunology: the immune system—second of two parts. N Engl J Med. 2000;343(2):108–17.

    Article  CAS  PubMed  Google Scholar 

  7. Jones D, O’Hara C, Kraus MD, et al. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood. 2000;96(2):685–90.

    CAS  PubMed  Google Scholar 

  8. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin’s lymphoma. Blood. 1997;89(12):4514–20.

    CAS  PubMed  Google Scholar 

  9. Rüdiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin’s lymphoma classification project. Ann Oncol. 2002;13(1):140–9.

    Article  PubMed  Google Scholar 

  10. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. J Clin Oncol. 1998;16(8):2780–95.

    CAS  PubMed  Google Scholar 

  11. Zaja F, Russo D, Silvestri F, et al. Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome. Haematologica. 1997;82(2):171–7.

    CAS  PubMed  Google Scholar 

  12. Ansell SM, Habermann TM, Kurtin PJ, et al. Predictive capacity of the international prognostic factor index in patients with peripheral T-cell lymphoma. J Clin Oncol. 1997;15(6):2296–301.

    CAS  PubMed  Google Scholar 

  13. Ascani S, Zinzani PL, Gherlinzoni F, et al. Peripheral T-cell lymphomas. clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. classification. Ann Oncol. 1997;8(6):583–92.

    Article  CAS  PubMed  Google Scholar 

  14. López-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification. Ann Oncol. 1998;9(8):849–55.

    Article  PubMed  Google Scholar 

  15. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15(10):1467–75.

    Article  CAS  PubMed  Google Scholar 

  16. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–9.

    Article  CAS  PubMed  Google Scholar 

  17. Tsuchiya T, Ohshima K, Karube K, et al. Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood. 2004;103(1):236–41.

    Article  CAS  PubMed  Google Scholar 

  18. Foss F, Carson KR, Federico M, et al. Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE), a new international treatment registry. Ann Oncol. Abstract 242, 2011;22(4).

  19. Vose JM, Neumann M, Harris ME. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes international T-cell lymphoma project. J Clin Oncol. 2008;26(25):4124–30.

    Article  PubMed  Google Scholar 

  20. Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915–23.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Piccaluga PP, Fuligni F, De Leo A, et al. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol. 2013;31(24):3019–25. This study validated the ability of gene expression profiles (GEPs; index test) in identifying different PTCL subtypes.

    Article  PubMed  Google Scholar 

  22. Federico M, Rudiger T, Bellei M, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31(2):240–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Mitrovic Z, Perry AM, Suzumiya J, et al. The prognostic significance of lymphopenia in peripheral T-cell and natural killer/T-cell lymphomas: a study of 826 cases from the International Peripheral T-cell Lymphoma Project. Am J Hematol. 2012;87(8):790–4.

    Article  PubMed  Google Scholar 

  24. Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-cell Lymphoma Project. Blood. 2011;118(1):148–55.

    Article  CAS  PubMed  Google Scholar 

  25. Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117(12):3402–8.

    Article  CAS  PubMed  Google Scholar 

  26. Iqbal J, Weisenburger DD, Chowdhury A, et al. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia. 2011;25(2):348–58.

    Article  CAS  PubMed  Google Scholar 

  27. Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115(5):1026–36.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Suzumiya J, Ohshima K, Tamura K, et al. The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-cell Lymphoma Project. Ann Oncol. 2009;20(4):715–21.

    Article  CAS  PubMed  Google Scholar 

  29. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral TCell Lymphoma Project. Blood. 2009;113(17):3931–7.

    Article  CAS  PubMed  Google Scholar 

  30. Federico M, Bellei M, Pesce E, et al. T-cell project: an international, longitudinal, observational study of patients with aggressive peripheral T-cell lymphoma. Rev Bras Hematol Hemoter. 2009;31(2):21–5.

    Google Scholar 

  31. Federico M, Bellei M., Pesce EA, et al. T-cell project: an international, prospective, observational study of patients with aggressive peripheral T-cell lymphoma. Analysis of first 524 patients. Ann Oncol. Abstract 241, 2011;22(4).

  32. Federico M, Bellei M, Pesce EA. T-cell project: an international, prospective, observational study of patients with aggressive peripheral NK/T-cell lymphoma: lesson from the first 1308 patients. Hematol Oncol Abstract 070. 2015;33:100–80.

    Article  Google Scholar 

  33. Foss FM, Carson KR, Pinter-Brown LC. Comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE): first detailed report of primary treatment. Blood, ASH Ann Meet Abstracts. 2012;120:1614.

    Google Scholar 

  34. Carson KR, Foss FM, Pinter-Brown LC, et al. Analysis of peripheral T-cell lymphoma (PTCL) subtype by race and geography using the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) dataset. Blood Abstract. 2013;122:4284.

    Google Scholar 

  35. Pinter-Brown LC, Foss FM, Carson KR, et al. Patient characteristics and initial treatment patterns in the United States for the most common subtypes of peripheral T-cell lymphoma (PTCL). Blood. ASH Ann Meet Abstract, 2014;124(21).

  36. Hsi ED, Gruver AM, Foss FM, et al. Biomarker quality assurance (QA) findings from the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) registry. Blood ASH Ann Meet Abstracts. 2012;120:4263.

    Google Scholar 

  37. Nabhan C, Foss FM, Horwitz SM. Characteristics and patterns of care of patients (pts) 70 years with T-cell non-Hodgkin lymphoma (TCL) in the United States (US). Hematol Oncol Abstract 232. 2015;33:181–243.

    Article  Google Scholar 

  38. Bellei M, Chiattone CS, Luminari S, et al. T-cell lymphomas in South America and Europe. Rev Bras Hematol Hemoter. 2012;34(1):42–7.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Federico M, Bellei M, Luminari S, et al. CD30 expression in peripheral T-cell lymphomas (PTCLs): a subset analysis from the international, prospective T-cell project. J Clin Oncol Abstract 8552, 2015;33(15).

  40. Horwitz SM, Bellei M, Marcheselli L. The role of transplant in the treatment of peripheral T-cell lymphomas (PTCLs): an analysis from the T-cell project database. Hematol Oncol Abstract 247. 2015;33:181–243.

    Article  Google Scholar 

  41. Pileri S, Bellei M, Vose JM. Evaluation of quality of biomarker data capture by peripheral sites in an international, cooperative study: analysis of 104 cases from the T-cell project. Blood ASH Ann Meet Abstracts. 2012;120:2650.

    Google Scholar 

  42. Bellei M, Marcheselli L, Pesce EA. Clinical characteristics and patterns of care of patients (pts) with peripheral T-cell lymphoma (PTCLs) according to age at time of diagnosis: a T-cell project snapshot. Hematol Oncol Abstract 231. 2015;33:181–231.

    Article  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Author notes

    Authors and Affiliations

    1. Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Centro Oncologico Modenese, Via del Pozzo 71, 41124, Modena, MO, Italy

      Monica Bellei, Emanuela Anna Pesce & Massimo Federico

    2. Section of Hematology and Oncology, Medical Director, Clinical Outpatient Cancer Center, The University of Chicago, 5841 South Maryland Ave MC2115, Chicago, IL, 60637, USA

      Chadi Nabhan

    3. Interdisciplinary Laboratory of Applied Research in Medicine (DReAM), University of Salento at the Hospital “V. FAZZI”, Piazza F. Muratore n.1, Palazzina Direzione Amministrativa, I Piano DReAM, 73100, Lecce, LE, Italy

      Luana Conte

    4. Division of Hematology/Oncology, University of Nebraska Medical Center|, Omaha, NE, 68198-7680, USA

      Julie M. Vose

    5. Yale Medical Oncology, Smilow Cancer Hospital at Yale—New Haven, South Frontage Road and Park Street, 7th Floor Multispecialty Care Center, New Haven, CT, 0651, USA

      Francine Foss

    Authors
    1. Monica Bellei
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Chadi Nabhan
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Emanuela Anna Pesce
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Luana Conte
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Julie M. Vose
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Francine Foss
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Massimo Federico
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Massimo Federico.

    Additional information

    This article is part of the Topical Collection on T-Cell and Other Lymphoproliferative Malignancies

    Monica Bellei and Chadi Nabhan contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Bellei, M., Nabhan, C., Pesce, E.A. et al. The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project. Curr Hematol Malig Rep 10, 448–455 (2015). https://doi.org/10.1007/s11899-015-0291-0

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s11899-015-0291-0

    Keywords

    Search

    Navigation